Stoke Therapeutics (STOK) EBITDA Margin Growth (1y) (2023 - 2026)
Powered by 
Analysis
Stoke Therapeutics (STOK) EBITDA Margin Growth (1y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -1,651.00 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 29,091.00 |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -50,407.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50,407.00 |
| Mar 31, 2026 | -92,772.00 |
| Dec 31, 2025 | -432,187.00 |
| Sep 30, 2025 | 20,776.00 |
| Jun 30, 2025 | 40,979.00 |
| Mar 31, 2025 | 74,311.00 |
| Dec 31, 2024 | 99,551.00 |
| Sep 30, 2024 | 21,022.00 |
| Jun 30, 2024 | 73,330.00 |
| Mar 31, 2024 | -19,373.00 |
| Dec 31, 2023 | -22,431.00 |
| Sep 30, 2023 | 11,125.00 |
| Jun 30, 2023 | -55,955.00 |
| Mar 31, 2023 | 34,727.00 |